论文标题
使用工程T细胞和IL-2在宫颈癌中研究剂量依赖性组合免疫疗法
Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
论文作者
论文摘要
基于T细胞的免疫疗法在癌症治疗中获得了显着的牵引力。尽管成功有限，但到目前为止，在治疗固体癌症方面，它越来越成功，证明具有更广泛的治疗潜力。在本文中，我们开发了一个数学模型，以研究靶向颈癌细胞系中E7抗原的工程T细胞受体（TCR）T细胞疗法的功效。我们考虑了遵循癌细胞，TCR T细胞和IL-2种群的动力系统。我们证明存在一个TCR T细胞剂量窗口，以成功消除癌症，该癌症可以根据初始肿瘤大小来表达。我们获得了两种宫颈癌细胞系的TCR T细胞剂量：4050和CASKI。最后，研究了TCR T细胞和IL-2治疗的联合疗法。我们表明，某些治疗方案可以改善4050细胞系中的治疗反应，但不能改善CASKI细胞系中的治疗反应。
Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its limited success, so far, in treating solid cancers, it is increasingly successful, demonstrating to have a broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines. We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2. We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell line, but not in the CaSki cell line.
